Jason L. Groves' departure as Chief Legal Officer of Medifast Inc was reported, effective May 29, 2026; the filing names no successor. As of November 6, 2026, Medifast Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 1, 2026, naming 1 departure (Form 8-K, June 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Medifast Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Medifast Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-01. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Medifast Inc files it.
Also on the record for Medifast Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 21, 2026 | Stake report, Schedule 13D/A, by Steamboat Capital Partners, LLC | 7.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Susquehanna Portfolio Strategies, LLC | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Kenneth Griffin | 2.6% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.6% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Citadel Securities GP LLC | 6.5% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5.74% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 6.96% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 20, 2026 | Stake report, Schedule 13D, by Steamboat Capital Partners, LLC | 6% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by G1 Execution Services, LLC | 1.4% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 7.06% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Medifast Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Medifast Inc and the records around it.
Medifast Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC also filed stake reports on 12 other companies: HAIN CELESTIAL GROUP INC (Aug 2026), Service Properties Trust (Aug 2026), TrueBlue, Inc. (Aug 2026)
- Citadel Securities GP LLC also filed stake reports on 24 other companies: CIPHER DIGITAL INC. (Oct 2026), First Solar, Inc. (Oct 2026), AmpliTech Group, Inc. (Oct 2026)
- G1 Execution Services, LLC also filed stake reports on 45 other companies: AmpliTech Group, Inc. (Aug 2026), Bitdeer Technologies Group (Aug 2026), Compass Diversified Holdings (Aug 2026)
Watch Medifast Inc
Get an email when Medifast Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Medifast Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Medifast Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Medifast Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-01 | Out | Chief Legal Officer | 2026-05-29 | 8-K, 2026-06-01 |
Who leads Medifast Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Legal Officer: Jason L. Groves, departure reported, effective 2026-05-29 (filed 2026-06-01). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Medifast Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Legal Officer at Medifast Inc, with the record behind each one.
Find candidates like Chief Legal Officer at Medifast IncEvery change, in the filing's words
Departing: Jason L. Groves, Chief Legal Officer, effective 2026-05-29
Effective as of May 29, 2026, Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc. (the "Company"), tendered his resignation from the Company.
- On May 31, 2026, Mr. Groves and the Company entered into a separation and release agreement (the "Separation Agreement") pursuant to which Mr. Groves will receive a one-time lump sum cash severance payment equal to one month of his annual base salary, less applicable taxes and withholdings, which payment is subject to Mr. Groves' non-revocation of the Separation Agreement and compliance with the terms and conditions set forth therein.
- Mr. Groves' departure was not the result of any disagreement with the Company nor any issue related to the Company's operations, policies or practices.
- In connection with Mr. Groves' departure, the Company has commenced a search for a permanent replacement.
Tools for this story
Each opens in a new tab, filled in for Medifast Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.